Growth Hormone Blood Test Explained: What It Measures and Why It's Requested

Growth hormone (GH, also called somatotropin) is a peptide hormone produced by somatotroph cells of the anterior pituitary gland. A "growth hormone test" refers to a laboratory measurement of GH concentration in blood, sometimes as a single sample and sometimes as a series of samples drawn during a dynamic protocol. This page summarises what the analyte is, how laboratories measure it, why clinicians request the test, and what published studies associate with high and low values. This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory result, symptom or treatment decision.

What the analyte is and where it comes from

GH is released from the anterior pituitary in discrete pulses, with the largest bursts typically occurring during sleep, and it circulates partly bound to growth hormone binding protein (GHBP). A review of GHBP described it as the circulating fragment of the GH receptor's extracellular domain, making it a reflection of GH receptor status as well as a factor that affects how much free hormone an assay encounters (PMID 11327370). Much of the downstream biological signal attributed to GH is mediated by insulin-like growth factor I (IGF-I), produced largely in the liver, which is why reviews of GH-axis assessment repeatedly discuss the two analytes together (PMID 33803429).

A further complication described in the literature is that GH is not a single molecular species. A review of GH isoforms reported that the hormone circulates as multiple variants and oligomers, and that these forms — together with assay interference — can influence the number a laboratory reports (PMID 30181896).

What the blood test measures

In routine practice the test is performed on serum or plasma using an immunoassay — historically radioimmunoassay, now more commonly chemiluminescent or immunometric "sandwich" platforms. The review of GH isoforms and assay interference reported that different assays recognise different GH forms to differing degrees, so results are not automatically interchangeable between methods or laboratories (PMID 30181896). Reviews of acromegaly diagnostics have emphasised the same point for the GH axis as a whole, noting that harmonisation of assays and of the reference preparations used to calibrate them is a recurring issue in biochemical diagnosis (PMID 41912292).

Single samples versus dynamic protocols

Because secretion is pulsatile, a single random GH value may be high or low simply as a function of when the blood was drawn. The literature therefore describes two broad strategies. When GH excess is suspected, suppression testing — classically measuring GH after an oral glucose load — is described in reviews of acromegaly biochemistry as a core element of diagnosis alongside IGF-I (PMID 33803429). When deficiency is suspected, the opposite approach is used: provocative stimulation tests, which a review of GH deficiency diagnosis described as the conventional means of demonstrating an inadequate GH response (PMID 20523017).

What is typically measured alongside GH

Why clinicians request growth hormone testing

Published reviews describe two principal clinical questions behind GH measurement.

Suspected growth hormone excess

Acromegaly — chronic GH excess, usually from a pituitary somatotroph adenoma — is the archetypal reason for GH testing in adults. A 2026 review of biochemical diagnosis in acromegaly summarised how GH and IGF-I measurements are combined to establish the diagnosis and to follow patients after treatment (PMID 41912292). An earlier review of the biochemical diagnosis of acromegaly discussed the same framework and the pitfalls that arise when GH and IGF-I results are discordant (PMID 33803429).

Suspected growth hormone deficiency

In children, a Danish review of GH deficiency described the diagnostic work-up as combining auxology, biochemistry and imaging rather than relying on a single hormone value (PMID 25352279). In adults, a review of testing for GH deficiency discussed provocative testing and the difficulty of defining deficiency biochemically in that population (PMID 20616504). A broader review of hypopituitarism described GH deficiency as one component of multi-axis pituitary failure that may follow tumours, surgery, radiotherapy or other pituitary injury (PMID 28299199).

What studies associate with high growth hormone values

The literature does not treat an elevated GH number as a diagnosis in itself. Reviews of acromegaly biochemistry described persistently elevated GH that fails to suppress appropriately, combined with an elevated age- and sex-adjusted IGF-I, as the biochemical pattern that supports GH excess, and noted that isolated elevated values can occur in people without pituitary disease (PMID 33803429). The 2026 review similarly framed diagnosis as a composite judgement based on more than one measurement rather than a single threshold (PMID 41912292).

Less common sources of GH excess are also described. A review of ectopic acromegaly set out the clinical and biochemical spectrum seen when GH-releasing hormone or, rarely, GH itself originates outside the pituitary, and discussed how this alters the biochemical picture (PMID 38413286). Comparative veterinary work has added context from other species: a review of acromegaly in dogs and cats described GH excess arising from different underlying mechanisms than those typical in humans (PMID 33727117).

What studies associate with low growth hormone values

A low random GH value is expected much of the time in healthy people, because between pulses circulating concentrations fall. This is why reviews of GH deficiency diagnosis describe stimulation testing rather than basal sampling as the usual approach: the review of GH deficiency diagnosis discussed the reliance on provocative tests and the limitations of the cut-offs applied to them (PMID 20523017). The adult-focused review reported similar concerns, noting that test selection and interpretation in adults carry their own difficulties (PMID 20616504).

Where pituitary structure or function is compromised, low GH output is described alongside other hormone deficits; the hypopituitarism review summarised advances in understanding the causes and assessment of such multi-hormone deficiency (PMID 28299199). Historical context is also available: a review of the history of GH treatment for GH deficiency in Japan traced how diagnosis and therapy for the condition developed over decades (PMID 28516747).

Assay interference and interpretation caveats: What Studies Report

Several recurring caveats appear across the verified literature.

• Isoform recognition and interference. Researchers reported that GH circulates in multiple isoforms and that assay interference can distort measured concentrations, which is relevant whenever an unexpected result appears (PMID 30181896).
• Assay and calibrator differences. Reviews of acromegaly biochemistry described variability between methods and the importance of consistent assay use when values are compared over time (PMID 41912292).
• Discordance between GH and IGF-I. The biochemical diagnosis review discussed cases in which GH and IGF-I results do not agree, and how such discordance complicates classification (PMID 33803429).
• Free versus bound IGF-I. The study of free IGF-I measurement examined whether the free fraction adds information beyond total IGF-I and reviewed the technical obstacles involved (PMID 17429595).
• Binding protein effects. The GHBP review described how binding protein concentrations relate to GH receptor status and therefore to interpretation of circulating hormone measurements (PMID 11327370).
• Provocative test limitations. Reviews of GH deficiency testing reported that stimulation test results depend on the agent used, on the cut-off applied and on patient factors, so a single number is not self-interpreting (PMID 20616504).

How results are used in context

Across the sources summarised here, biochemical testing of the GH axis is presented as one input among several. The paediatric review described growth velocity and clinical assessment as integral to the evaluation rather than optional extras (PMID 25352279), and the acromegaly reviews described imaging and clinical features sitting alongside GH and IGF-I results (PMID 33803429). Where an unusual source of hormone excess is suspected, the ectopic acromegaly review described additional biochemical steps used to localise the origin (PMID 38413286).

No reference ranges or decision thresholds are reproduced on this page. Cut-offs vary by assay, by laboratory, by age and sex, and by the specific protocol used, and the reviews cited above consistently treat them as method-dependent (PMID 41912292). Any individual result belongs with the ordering clinician, who has access to the clinical context, the assay used and the rest of the laboratory panel.

Limitations of this overview

The sources summarised here are reviews and diagnostic overviews rather than head-to-head outcome trials, and several focus on specific populations — children, adults with pituitary disease, or, in one case, companion animals (PMID 33727117). Findings described for one population do not automatically transfer to another. Readers interested in the primary material can follow the PubMed links below to the abstracts, where the scope and methods of each paper are stated by its authors.

References

• Acromegaly: Biochemical diagnosis (Vitamins and Hormones, 2026)
• The Biochemical Diagnosis of Acromegaly (Journal of Clinical Medicine, 2021)
• The clinical and biochemical spectrum of ectopic acromegaly (Best Practice & Research Clinical Endocrinology & Metabolism, 2024)
• Acromegaly in dogs and cats (Annales d'Endocrinologie, 2021)
• Growth hormone: isoforms, clinical aspects and assays interference (Clinical Diabetes and Endocrinology, 2018)
• Growth hormone binding protein 2001 (Journal of Pediatric Endocrinology & Metabolism, 2001)
• Diagnosis of growth hormone deficiency (Endocrine Development, 2010)
• Testing growth hormone deficiency in adults (Frontiers of Hormone Research, 2010)
• [Growth hormone deficiency in children] (Ugeskrift for Laeger, 2014)
• Advances in understanding hypopituitarism (F1000Research, 2017)
• Utility of free IGF-I measurements (Pituitary, 2007)
• The History of Growth Hormone Treatment for GHD in Japan (Pediatric Endocrinology Reviews, 2017)